Wrong and nobody can prodoce a signed copy of that STA as the hearing to approve it never happened. Another blatant fairytale backed by nothing .
LCY Biosciences requested to be assigned the right to use the technology. It was granted pursuant to the STA agreement.
Here are the facts as plainly spelled out in court filings .
As outlined in previous reports, the Company retained some of its intellectual property rights, including rights under certain development licensing agreements with Cargill Incorporated (“Cargill”), as well as non-assertion agreements with Reverdia V.O.F. (“Reverdia”) and Mitsubishi Chemical Corporation (“MCC”). The Monitor has canvassed prospective parties in exploring options to realize value from these agreements and the rights thereunder held by BioAmber Inc. The Monitor anticipates the efforts and costs to continue to hold and pursue the realization of these agreements, coupled with the material and accruing cure costs connected therein, outweigh any potential benefit to the Company and its stakeholders.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.